Tumors have different levels of NQO1 compared to normal tissue, and compounds containing NQO1-activated quinone pharmacophore should have significant tumor selectivity, which may lead to the development of NQO1-directed antitumor agents (Ross and Siegel, 2021). This evidence concerns the gene NQO1 and neoplasm.